Sientra, Inc.: directors' dealings · United States · SEC (Form 4)

About Sientra, Inc.

Sientra, Inc. is a United States medical device company focused on surgical aesthetics and breast reconstruction. The business was founded in 2007 and built its brand around a premium portfolio for plastic surgeons, with an emphasis on clinical data, product safety, and technical innovation. Sientra was headquartered in Irvine, California, United States, and was listed on NASDAQ under the ticker SIEN. A key recent development is that the company entered Chapter 11 in February 2024 and subsequently pursued a Section 363 asset sale, which materially changes how investors should view the name, its equity story, and its operating footprint. ([investors.sientra.com](https://investors.sientra.com/overview/?utm_source=openai)) Operationally, Sientra focused on breast implants, tissue expanders, fat grafting solutions, and adjacent products used in plastic surgery. Its portfolio included round and shaped silicone breast implants, the AlloX2 and AlloX2Pro tissue expanders, the Viality fat transfer system, the SimpliDerm human acellular dermal matrix, and BIOCORNEUM scar gel. The company repeatedly highlighted FDA-approved products for the U.S. market and positioned its offering around differentiated clinical performance and surgeon preference. ([investors.sientra.com](https://investors.sientra.com/overview/?utm_source=openai)) From a competitive standpoint, Sientra aimed to be a specialized alternative to larger breast implant and surgical-aesthetics players in the United States. Its strategy relied on surgeon relationships, clinical credibility, and an integrated product platform spanning augmentation and reconstruction. Management also used acquisitions and product extensions to broaden the addressable market, including the OPUS implant manufacturing operation, AuraGen fat grafting technology, and the SimpliDerm partnership. These steps were intended to deepen the company’s presence in reconstructive and aesthetic surgery workflows. ([investors.sientra.com](https://investors.sientra.com/overview/?utm_source=openai)) Recent history is dominated by the 2024 restructuring. Sientra filed for Chapter 11 on February 12, 2024, received a Nasdaq delisting notice, and then completed a Section 363 auction process in which Tiger Aesthetics Medical was selected as the winning bidder for the breast reconstruction and augmentation assets, while Nuance Intermediary acquired substantially all assets tied to BIOCORNEUM. For investors, that means Sientra is best understood as a legacy public-company case study in medical-device consolidation and distressed asset monetization rather than a straightforward operating growth story. ([investors.sientra.com](https://investors.sientra.com/news/news-details/2024/Sientra-to-Pursue-Strategic-Sale-of-its-Business-Through-Voluntary-Chapter-11-Process/default.aspx?utm_source=openai))